Bristol Myers Squibb's Devens site, a specialist in complex biologics and cell therapies, aimed to overcome the scientific complexity and variability inherent to its business which is based on living cells. Building on traditional methods, the site merged biopharma science with AI and digital strategies to create more than 30 new use cases. This approach boosted the company's performance, resulting in a 42% reduction in New Product Introduction (NPI) time, a volume increase of over 40%, and a cut in emissions of more than 40%.